Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 170 for:    "Acute Lymphocytic Leukemia" | "Etoposide"

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00022737
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : February 27, 2014
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Condition or disease Intervention/treatment Phase
Childhood Acute Lymphoblastic Leukemia in Remission Recurrent Childhood Acute Lymphoblastic Leukemia Biological: filgrastim Drug: asparaginase Drug: cyclophosphamide Drug: cyclosporine Drug: cytarabine Drug: daunorubicin hydrochloride Drug: dexamethasone Drug: etoposide Drug: ifosfamide Drug: imatinib mesylate Drug: leucovorin calcium Drug: mercaptopurine tablet Drug: methotrexate Drug: pegaspargase Drug: vincristine sulfate Procedure: allogeneic bone marrow transplantation Procedure: peripheral blood stem cell transplantation Procedure: umbilical cord blood transplantation Radiation: radiation therapy Phase 3

  Hide Detailed Description

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the feasibility of treatment with intensified chemotherapy, in terms of toxicity and patient accrual, in children with very high-risk acute lymphoblastic leukemia.

II. Determine the feasibility and efficacy of following intensified chemotherapy with allogeneic hematopoietic stem cell transplantation in patients with HLA-matched related donors.

III. Determine the toxicity of imatinib mesylate in combination with intensified chemotherapy in Philadelphia chromosome-positive patients.

IV. Determine the event-free survival of patients treated with this regimen. V. Determine whether minimal residual disease (MDR) after induction therapy and prior to intensification therapy can predict relapse in these patients.

VI. Determine whether MDR after intensification is prognostically significant. VII. Determine whether gene expression patterns predict disease recurrence or response to imatinib mesylate.

OUTLINE: This is a multicenter study. This is also a dose-escalation study of imatinib mesylate in Philadelphia chromosome-positive (Ph+) patients. Patients are stratified according to Philadelphia chromosome (Ph) status (Ph-positive vs Ph-negative or indeterminate), hypodiploidy (yes vs no), MLL translocation (11q23) AND slow early response to prior induction therapy (yes vs no), and failed prior induction therapy (yes vs no).

Cohorts of 8-12 Ph+ patients receive escalating doses of imatinib mesylate, according to the guidelines for each treatment block of this study, until the maximum tolerated dose (MTD) for each treatment combination is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 35 patients are treated at the MTD.

CONSOLIDATION BLOCK 1: Patients receive etoposide IV over 1 hour followed by ifosfamide IV over 1.5 hours on days 1-5. Patients also receive methotrexate intrathecally on day 1 and filgrastim (G-CSF) subcutaneously (SC) on days 6-15 or until blood counts recover. Patients with CNS 2/3 at diagnosis also receive intrathecal triple therapy comprising methotrexate, hydrocortisone, and cytarabine (ITT) on days 8 and 15. Ph+ patients in cohorts 3, 4, and 5 receive oral imatinib mesylate on days 1-21. Within 4 days of starting consolidation therapy, patients with biopsy-proven testicular leukemia undergo radiotherapy daily for 12 days.

CONSOLIDATION BLOCK 2: Patients receive high-dose methotrexate IV over 24 hours and ITT on day 1 followed by high-dose cytarabine IV over 3 hours, every 12 hours on days 2 and 3. Patients also receive leucovorin calcium IV or orally every 6 hours for 3 doses beginning on day 2, and G-CSF SC on days 4-13 or until blood counts recover. Ph+ patients in cohorts 2, 3, 4, and 5 receive oral imatinib mesylate as in consolidation block 1. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) proceed to preparative chemotherapy. All other patients proceed to reinduction block 1.

REINDUCTION BLOCK 1: Patients receive vincristine IV on days 1, 8, and 15; daunorubicin IV on days 1 and 2; cyclophosphamide IV over 30 minutes, every 12 hours on days 3 and 4; pegaspargase intramuscularly (IM) on day 4; and ITT on days 1 and 15. Patients also receive oral dexamethasone twice daily on days 1-7 and 15-21 and G-CSF SC on days 5-14 or until blood counts recover. Ph+ patients in cohorts 2, 4, and 5 receive imatinib mesylate as in consolidation block 1.

INTENSIFICATION BLOCK 1: Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and ITT on days 1 and 22. Patients also receive leucovorin calcium IV or orally every 6 hours for 3 doses beginning on days 2 and 16. Patients receive etoposide IV over 2 hours followed by cyclophosphamide IV over 30 minutes on days 22-24; G-CSF SC on days 27-36 or until blood counts recover; high-dose cytarabine IV over 3 hours, every 12 hours on days 43 and 44; and asparaginase IM on day 44. Ph+ patients in cohorts 1 and 4 receive oral imatinib mesylate on days 43-63, and patients in cohort 5 receive oral imatinib mesylate on days 1-56.

REINDUCTION BLOCK 2: Patients receive vincristine, daunorubicin, cyclophosphamide, pegaspargase, dexamethasone, and G-CSF as in reinduction block 1. Patients also receive ITT on days 1 and 15. Ph+ patients receive imatinib mesylate as in reinduction block 1.

INTENSIFICATION BLOCK 2: Patients receive methotrexate, leucovorin calcium, etoposide, cyclophosphamide, filgrastim, cytarabine, and asparaginase as in intensification block 1. Ph+ patients receive imatinib mesylate as in intensification block 1.

MAINTENANCE 1: Patients receive high-dose methotrexate IV and leucovorin calcium as in consolidation block 2. Patients also receive ITT and vincristine IV on days 1 and 29; oral dexamethasone twice daily on days 1-5 and 29-33; oral methotrexate on days 8, 15, and 22; oral mercaptopurine on days 8-28; etoposide IV over 2 hours followed by cyclophosphamide IV over 30 minutes on days 29-33; and G-CSF SC on days 34-43. Ph+ patients in cohorts 1-4 receive oral imatinib mesylate on days 29-49 and patients in cohort 5 receive oral imatinib mesylate on days 1-56. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE 2: Patients receive vincristine and dexamethasone as in maintenance 1. Beginning on day 1, patients undergo cranial radiotherapy once daily, 5 days a week, for approximately 2 weeks. Patients also receive oral methotrexate on days 8, 15, 22, 29, 36, 43, and 50 and oral mercaptopurine on days 11-56. Ph+ patients in cohorts 1-4 receive oral imatinib mesylate on days 1-21 and 29-49, and patients in cohort 5 receive oral imatinib mesylate on days 1-56.

MAINTENANCE 3: Patients receive vincristine and dexamethasone as in maintenance 2. Patients also receive oral methotrexate on days 1, 8, 15, 22, 29, 36, 43, and 50; and oral mercaptopurine on days 1-56. Ph+ patients receive imatinib mesylate as in maintenance 2. Treatment repeats every 8 weeks for 7 courses (12 courses total in maintenance 1, 2, and 3) in the absence of disease progression or unacceptable toxicity.

Patients may undergo allogeneic HSCT after consolidation block 2 if there is an available HLA-DR matched or HLA-A or -B matched or 1 antigen mismatched relative donor.

Patients with CNS leukemia undergo cranial radiotherapy 3 times daily on days -10 to -8. All patients undergo radiotherapy twice daily on days -7 to -5 and receive etoposide IV on day -4 and cyclophosphamide IV on days -3 and -2. Patients undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation on day 0. Patients receive cyclosporine IV beginning on day -1 and continuing every 12 hours, switching to oral administration when possible, until day 60 and tapering thereafter. Patients also receive methotrexate on days 1, 3, and 6. Beginning 16-24 weeks after transplantation, Ph+ patients receive oral imatinib mesylate once daily for 24 weeks.

Patients are followed every 4-8 weeks for 1 year, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter. Patients undergoing HSCT are followed weekly for the first year.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051)
Study Start Date : October 2002
Actual Primary Completion Date : October 2006


Arm Intervention/treatment
Experimental: Arm I
See Design Details.
Biological: filgrastim
Given SC
Other Names:
  • G-CSF
  • Neupogen

Drug: asparaginase
Given IM
Other Names:
  • ASNase
  • Colaspase
  • Crasnitin
  • Elspar
  • L-ASP

Drug: cyclophosphamide
Given IV
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana

Drug: cyclosporine
Given IV
Other Names:
  • ciclosporin
  • cyclosporin
  • cyclosporin A
  • CYSP
  • Sandimmune

Drug: cytarabine
Given IT and IV
Other Names:
  • ARA-C
  • arabinofuranosylcytosine
  • arabinosylcytosine
  • Cytosar-U
  • cytosine arabinoside

Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • Cerubidin
  • Cerubidine
  • daunomycin hydrochloride
  • daunorubicin
  • RP-13057

Drug: dexamethasone
Given orally
Other Names:
  • Aeroseb-Dex
  • Decaderm
  • Decadron
  • DM
  • DXM

Drug: etoposide
Given IV
Other Names:
  • EPEG
  • VP-16
  • VP-16-213

Drug: ifosfamide
Given IV
Other Names:
  • Cyfos
  • Holoxan
  • IFF
  • IFX
  • IPP

Drug: imatinib mesylate
Given orally
Other Names:
  • CGP 57148
  • Gleevec
  • Glivec

Drug: leucovorin calcium
Given IV or orally
Other Names:
  • CF
  • CFR
  • LV

Drug: mercaptopurine tablet
Given orally
Other Names:
  • 6-mercaptopurine
  • 6-MP
  • Leukerin
  • MP

Drug: methotrexate
Given IT, IV, and orally
Other Names:
  • amethopterin
  • Folex
  • methylaminopterin
  • Mexate
  • MTX

Drug: pegaspargase
Given IM
Other Names:
  • L-asparaginase with polyethylene glycol
  • Oncaspar
  • PEG-ASP
  • PEG-L-asparaginase

Drug: vincristine sulfate
Given IV
Other Names:
  • leurocristine sulfate
  • VCR
  • Vincasar PFS

Procedure: allogeneic bone marrow transplantation
Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
Other Names:
  • bone marrow therapy, allogeneic
  • bone marrow therapy, allogenic
  • transplantation, allogeneic bone marrow
  • transplantation, allogenic bone marrow

Procedure: peripheral blood stem cell transplantation
Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
Other Names:
  • PBPC transplantation
  • PBSC transplantation
  • peripheral blood progenitor cell transplantation
  • transplantation, peripheral blood stem cell

Procedure: umbilical cord blood transplantation
Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
Other Names:
  • cord blood transplantation
  • transplantation, umbilical cord blood
  • UCB transplantation

Radiation: radiation therapy
Undergo radiation therapy
Other Names:
  • irradiation
  • radiotherapy
  • therapy, radiation




Primary Outcome Measures :
  1. Feasibility, in terms of patient accrual [ Time Frame: Up to 1.75 years ]
    As a target goal, we wish to enroll at least 80% of the potential available patients. The accrual duration for this pilot study will be based on accruing adequate numbers to complete the dose escalation study in the Ph+ subset. The planned study accrual duration should be approximately 1.75 years.

  2. Feasibility, in terms of incidence of adverse events graded according to NCI CTC v 2.0 [ Time Frame: Up to 7 years ]
    The use of imatinib as given in combination with other agents in a particular cohort will be considered feasible initially if 5 or more of the first 6 evaluable patients complete the phase(s) without evidence of grade 3 or 4 targeted toxicities.


Secondary Outcome Measures :
  1. Event-free survival [ Time Frame: Up to 7 years ]
    Estimated with 90% confidence interval.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of acute lymphoblastic leukemia
  • Received prior front-line therapy on a Pediatric Oncology Group (POG),Children's Cancer Group (CCG), or Central Oncology Group (COG) study
  • Received induction therapy comprising vincristine, asparaginase, prednisone/dexamethasone, and daunorubicin as in CCG, POG, or COG protocols
  • M1 or M2 bone marrow status after front-line induction therapy and presenting with at least 1of the following:

    • Philadelphia chromosome positive (Ph+) with t(9;22)(q34;q11) by cytogenetics or fluorescence in situ hybridization
    • bcr-abl fusion transcript by reverse transcription polymerase chain reaction
    • Hypodiploid with less than 44 chromosomes and/or DNA index less than0.81
    • MLL translocation (11q23) by cytogenetics and a slow early response (SER) to induction therapy, defined as at least 5% blasts at day 15 of induction and/or at least .1% minimal residual disease (MRD) after induction therapy
  • Failed to achieve remission after front-line induction therapy

    • M3 bone marrow status (greater than 25% blasts) after induction therapy
    • M2 bone marrow status (5-25% blasts) or at least 1% MRD after induction therapy and M2 or M3or at least 1% MRD after consolidation therapy (CCG studies) or extended induction therapy (POG or COG studies)
  • See Disease Characteristics
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • See Disease Characteristics
  • See Disease Characteristics
  • No concurrent prophylactic cranial radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00022737


Locations
Layout table for location information
United States, California
Children's Oncology Group
Arcadia, California, United States, 91006-3776
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Kirk Schultz Children's Oncology Group

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00022737     History of Changes
Other Study ID Numbers: NCI-2012-01862
NCI-2012-01862 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CDR0000068859
COG-AALL0031
AALL0031 ( Other Identifier: Children's Oncology Group )
AALL0031 ( Other Identifier: CTEP )
U10CA098543 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: February 27, 2014
Last Verified: November 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Etoposide
Leukemia
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cytarabine
Cyclosporine
Dexamethasone
Cyclophosphamide
Methotrexate
Vincristine
Imatinib Mesylate
Ifosfamide
Daunorubicin
Asparaginase
Mercaptopurine
Pegaspargase
Cyclosporins
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids